Follicular lymphoma (FL) accounts for up to 30% of all lymphomas and is the second most common non-Hodgkin lymphoma (NHL). The pathophysiology of FL is complex and limited therapeutic options are available. Recently, the USFDA has approved a methyltransferase inhibitor drug for FL The FDA granted accelerated approval to tazemetostat, a methyltransferase inhibitor, for relapsed or refractory (R/R) follicular lymphoma (FL) in adults.
The drug was approved for: Patients with a positive Enhancer of zeste homolog 2 (EZH2) mutation, as detected by an FDA-approved test; Patients treated with at least two prior systemic therapies; and Patients with wild-type FL and with no satisfactory alternative treatment options. The approval of the drug was based on the positive results of two open-label, single-arm multi-center trials. Patients with confirmed diagnoses of FL after at least two prior…
